TNF in the era of immune checkpoint inhibitors: friend or foe?

Immune checkpoint inhibitors (ICIs) are effective in the treatment of patients with advanced cancer and have emerged as a pillar of standard cancer care. However, their use is complicated by adverse effects known as immune-related adverse events (irAEs), including ICI-induced inflammatory arthritis....

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature reviews. Rheumatology Jg. 17; H. 4; S. 213 - 223
Hauptverfasser:	Chen, Allen Y, Wolchok, Jedd D, Bass, Anne R
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States Nature Publishing Group 01.04.2021
Schlagworte:	Adverse events Arthritis Arthritis - chemically induced Arthritis - immunology Cancer Drug Interactions Drug Synergism Drug-Related Side Effects and Adverse Reactions - immunology Glucocorticoids Humans Immune checkpoint inhibitors Immune Checkpoint Inhibitors - adverse effects Immune Checkpoint Inhibitors - therapeutic use Immunotherapy - methods Inflammation - chemically induced Inflammation - drug therapy Inflammatory bowel diseases Intestine Neoplasms - drug therapy Neoplasms - immunology Patients Rheumatoid arthritis Risk Assessment Safety Spondyloarthropathy TNF inhibitors Tumor necrosis factor Tumor Necrosis Factor Inhibitors - adverse effects Tumor Necrosis Factor Inhibitors - pharmacology Tumor Necrosis Factor Inhibitors - therapeutic use Tumor Necrosis Factor-alpha - immunology
ISSN:	1759-4790, 1759-4804, 1759-4804
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!